eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Review paper

PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review

Michał Adamczyk
1
,
Dorota Krasowska
1

1.
Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland
Adv Dermatol Allergol 2021; XXXVIII (6): 925–930
Online publish date: 2022/01/07
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Programmed-death 1 (PD-1) is a co-receptor that inhibits the inflammatory response, and thus helps in maintenance of peripheral immunotolerance. Impairment in the PD-1/PD-L1 pathway is believed to play an important role in many immune-mediated diseases, including systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and autoimmune hepatitis, and, as emphasized recently, in psoriasis and psoriatic arthritis. Biologic drugs targeting immune checkpoint regulators may be associated with new-onset psoriasis or exacerbations of pre-existing dermatosis. In this review we discuss the role of PD-1/PD-L1 pathway in psoriasis basing on data published to date.
keywords:

psoriasis, psoriatic arthritis, PD-1/PD-L1, immune checkpoint

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.